We conducted an open prospective clinical trial to evaluate the efficacy and toxicity of trimethoprimsulfamethoxazole given as one double-strength tablet thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia (PCP) in human immunodeficiency virus-infected (HIV+) patients. A total of 104 HIV+ patients were evaluated, with 74 being in the primary prophylaxis group and 30 being in the secondary prophylaxis group. All except six patients received concomitant zidovudine; five patients on primary prophylaxis and one patient on secondary prophylaxis refused zidovudine. There were 70 patients evaluated for the efficacy of primary prophylaxis. The mean CD4 count was 124.4 + 110.1 cells per ,ul. The mean follow-up time was 11.8 + 5.8 months (median, 12 months; range, 1 to 32 months). Two noncompliant patients developed PCP after 1 and 3 months of chemoprophylaxis. The failure rate (under the intention to treat principle) was 2 of 70 patients (2.9%; 95% confidence interval, 0.35 to 10%), or 1 per 413 patient-months of observation. There were 27 patients evaluated for the efficacy of secondary prophylaxis. The mean follow-up time was 12.4 + 7.2 months (median, 11 months; range, 1 to 29 months). Two patients, one of whom was noncompliant, were treatment failures, developing PCP after 14 and 15 months of chemoprophylaxis; this gave a failure rate of 2 of 27 patients (7.4%; 95% confidence interval, 0.9 to 24.3%), or 1 per 167 patient-months of observation. Adverse reactions sufficient to permanently terminate therapy occurred in 9 of 104 patients (8.7%; 95% confidence interval, 4 to 15.7%) overall. The serum trimethoprim, sulfamethoxazole, and N4-acetylsul--famethoxazole concentrations measured by high-pressure liquid chromatography were uniformly low. One double-strength tablet of trimethoprim-sulfamethoxazole taken weekly on Monday, Wednesday, and Friday appeared to be well tolerated and efficacious for the prophylaxis of PCP in HIV+ patients at high risk and deserves further investigation.
high incidence of adverse reactions with trimethoprim-sulfamethoxazole (2) and the high cost and inconvenience of use with aerosolized pentamidine have limited the use of chemoprophylaxis in certain patients.
In our institutions, the use of one DS tablet of trimethoprim-sulfamethoxazole (co-trimoxazole; 160 mg of trimethoprim and 800 mg of sulfamethoxazole) thrice weekly for PCP prophylaxis became common practice in early 1988. The rationale for this approach was based on the clinical evidence that a lower dose could reduce adverse reactions but maintain the drug's efficacy. Several studies support this supposition. An intermittent regimen of trimethoprim-sulfamethoxazole thrice weekly had an efficacy comparable to that of daily dosing for primary prophylaxis in pediatric oncology patients (7) . These children received trimethoprim (150 mg/M2) and sulfamethoxazole (750 mg/M2) up to the equivalent of two DS tablets daily. However, this dosing scheme cannot be directly extrapolated to adult patients. The volumes of distribution of trimethoprim and sulfamethoxazole per body weight or body surface area are larger in children compared with those in adults, resulting in higher dose requirements in the former population (12, 17) . Siber et al. (17) demonstrated that, on a milligram per kilogram of body weight basis, adults need only 60% of the pediatric dose of intravenous trimethoprim-sulfamethoxazole to achieve equivalent concentrations of each drug component in serum. Therefore, we rationalized that a chemoprophylactic dose of trimethoprim-sulfamethoxazole in adults would be approximately 60% of the dosage requirements documented by Hughes et al. (7) . In light of the need for an effective, convenient, and inexpensive chemoprophylaxis for PCP, we report our experience with the use of one DS tablet of trimethoprim-sulfamethoxazole taken orally on Monday, Wednesday, and Friday of each week without concomitant leucovorin. This regimen was used for both primary and secondary prophylaxis of PCP in HIV+ individuals who were at high risk for developing this disease and who were known not to be allergic to trimethoprim-sulfamethoxazole.
(This study was presented in part at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy [18] Pharmacology. A subgroup of 12 patients from the population described above gave informed consent for a separate study approved by the Institutional Review Board of the University of Tennessee for determination of concentrations of trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole in serum by an ion-paired high-pressure liquid chromatography assay with solid-phase extraction (8) . The limits of detectability for this assay were as follows: trimethoprim, 25 ng/ml; sulfamethoxazole, 250 ng/ml; and N4-acetylsulfamethoxazole, 25 ng/ml. The intra-and interassay coefficients of variation were <6% and <9%, respectively.
Statistics. All means are expressed as + standard deviations. Categorical data were compared by the chi-square test with the Yates correction. Exact 95% confidence intervals (exact confidence limits for P) were obtained from standard tables (9) .
RESULTS
There were 75 patients eligible for primary prophylaxis and 37 patients eligible for secondary prophylaxis with lowdose thrice-weekly trimethoprim-sulfamethoxazole therapy determined by chart review. All except six patients were on concomitant zidovudine therapy. Five patients receiving primary prophylaxis and one patient receiving secondary prophylaxis refused zidovudine therapy. The zidovudine dosage was generally 1,200 mg/day prior to August 1989 (the time of the National Institutes of Health's A Note to Physicians [14] ) and generally 500 mg/day thereafter, with dosage and therapy determined by the patient's tolerance.
Primary prophylaxis. Of the 75 eligible patients on primary prophylaxis, drug efficacy could be evaluated in 70 of them and toxicity could be evaluated in 74 of them. Four were excluded from the efficacy evaluation because all had CD4 counts of >380 cells per ,ul at the time of initiation of prophylactic therapy. One patient was excluded from both efficacy and toxicity evaluation since he was receiving concomitant therapy with another agent with antipneumocystis activity (pyrimethamine-sulfa).
The demographic characteristics of the patients in the primary prophylaxis group (n = 70) are given in On follow-up of the 70 patients, 13 patients died, but none of these patients had suspected PCP at the time of death (as noted by a review of their records, discussions with their attending physicians, or both), and 11 patients were lost to follow-up. The mean follow-up time for the group (as of 31 January 1991) was 11.8 ± 5.8 months, with a median follow-up time of 12 months (range, 1 to 32 months). There were only two patients who developed PCP, after 1 and 3 months on therapy, with CD4 counts of 33 and 220 cells per ,ul 1 and 3.5 months earlier, respectively. In both cases, the treating physician felt that the patients were noncompliant with their medications. In the failure at 3 months, the pharmacy records and the patient confirmed the physician's evaluation. In the failure at 1 month, no pharmacy records indicating that the prescription was filled could be found, but an outside pharmacy may have been used. The failure rate was (under the intention to treat principle) 2 of 70 patients (2.9%, 95% confidence interval [CI], 0.35 to 10%), or 1 per 413 patient-months of observation.
Secondary prophylaxis. Of the 37 patients eligible for secondary prophylaxis, 30 started trimethoprim-sulfamethoxazole, 3 elected therapy with aerosolized pentamidine, and 4 refused any therapy. Two patients were lost to follow-up in <1 month. In addition, for one patient, trimethoprim-sulfamethoxazole was stopped in <3 weeks secondary to increased liver function tests; trimethoprim-sulfamethoxazole was subsequently restarted at twice a week by his physician without a recurrence of symptoms. Therefore, 27 patients on secondary prophylaxis were evaluated for the efficacy of therapy and 30 were evaluated for the toxicity of therapy. The demographic characteristics for the secondary prophylaxis group (n = 27) are given in large controlled studies (Table 3) . Data from the Multicenter AIDS Cohort Study (15) indicate that 18.4% of HIV+ patients develop PCP within 1 year when the CD4 lymphocyte count (as measured at 6-month intervals) is <200 cells per p.l, or <20% of lymphocytes. The primary prophylaxis study of Hirschel et al. (6), with 78% of the patients receiving placebo having a CD4 cell count at the time of entry into the study of <200 cells per ,ul, more closely resembles our primary prophylaxis group and had a PCP incidence of 27.1% per year of observation. A small percentage of patients with CD4 cell counts of >200 cells per ,ul do develop PCP, as noted in this and prior studies (6, 10, 15) . In contrast to the data from the Multicenter AIDS Cohort Study (15) and Hirschel et al. (6) , in our primary prophylaxis group (mean follow-up time, 11.8 months; median follow-up time, 12 months) we observed a PCP occurrence of 2.9%. However, this comparison is limited by the effect of zidovudine on the progression of disease, as up to 93% of the patients in the primary prophylaxis group of this study were on zidovudine, whereas only 9% of the patients in the Multicenter AIDS Cohort Study (15) and up to 78% of the patients in the study of Hirschel et al. (6) were on zidovudine. If compliance and the probability that the development of PCP in <1 month of therapy is likely to be -due to preexisting infection are considered, then there were no treatment failures in the primary prophylaxis group in this study. The relapse rate at 8 months after the first episode of PCP in the absence of prophylaxis in patients on zidovudine therapy is approximately 50%, and at 12 months it is 66% (1, 13); our observed rate was 7.4% at a mean of 12.4 months.
Adverse reactions were mild and, overall, lead to therapy being permanently discontinued in 8.7% of patients (Table  3) . Although the incidence of adverse reactions was higher in the secondary prophylaxis group, it did not achieve statistical significance (P > 0.25). In an additional six patients (5.8%), suspected adverse reactions did not recur on rechallenge with trimethoprim-sulfamethoxazole and were therefore unlikely to be drug related. It is unknown whether the overall incidence of adverse reactions that were presumed to be drug related would have been lower if all patients had been rechallenged. (6) . Although adverse reactions resulting in the discontinuation of therapy with aerosolized pentamidine were low (6, 10), the expense, inconvenience, and higher failure rate in patients on secondary prophylaxis (10, 13 ) and a possible short-term survival benefit with trimethoprim-sulfamethoxazole would favor the use of low-dose trimethoprim-sulfamethoxazole as the initial method of prophylaxis. If our results are corroborated by other investigators in larger comparative controlled studies of longer duration, then this method of chemoprophylaxis, which is both inexpensive and convenient, should become a standard regimen for the chemoprophylaxis of PCP.
